Business UpdateMay 13, 2026, 04:12 PM
Aptevo Reports Strong Mipletamig Data; Secures $60M Equity Line
AI Summary
Aptevo Therapeutics provided a Q1 2026 business update, highlighting strong clinical data for its lead candidate, Mipletamig, in frontline acute myeloid leukemia (AML). The company reported an 87% clinical benefit rate and 81% remission (CR or CRi) with no cytokine release syndrome. Aptevo also secured a $60 million equity line of credit, enhancing financial flexibility through 2029, and completed an executive leadership transition with Jeff Lamothe appointed CEO.
Key Highlights
- Mipletamig demonstrated an 87% clinical benefit rate in frontline AML patients.
- Mipletamig achieved 81% complete remission (CR or CRi) in frontline AML patients.
- No cytokine release syndrome (CRS) was observed in frontline AML patients treated with Mipletamig.
- Aptevo secured a $60 million Standby Equity Purchase Agreement (SEPA) for financial flexibility.
- Cash and cash equivalents were $14.5 million as of March 31, 2026.
- Jeff Lamothe was appointed President and CEO, with Marvin White transitioning to Executive Chair.
- The RAINIER trial is on track for completion and Phase 2 dose selection by year-end 2026.